Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study

RCT (n=568) found addition of ipilimumab to pembrolizumab in the first line setting did not improve progression free survival (8.4 vs 8.4 months; 1.06; 95% CI, 0.86 to 1.30; P = 0.72) or overall survival (21.4 vs 21.9 months; 1.08; 0.85 to 1.37; P = 0.74) vs placebo.

Source:

Journal of Clinical Oncology